Company Filing History:

7 out of 1,858

Takeda Chemical Industries, Inc.

patents

6 out of 1,177

Takeda Pharmaceutical Company Limited

patents

Years Active: 1999-2011

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7943137 - FPRL1 ligands and use thereof (2011-05-17),

2. 7799533 - Polypeptides, their production and use (2010-09-21),

3. 7517661 - Methods of screening for ligands for FPRL2 (2009-04-14),

4. 7410776 - Polypeptides, their production and use (2008-08-12),

5. 7217808 - RFRP-3 and DNA thereof (2007-05-15),

6. 7041789 - RFRP-3 and DNA thereof (2006-05-09),

7. 6881545 - Polypeptides, their production and use (2005-04-19),

8. 6794491 - Polypeptides, their production and use (2004-09-21),

9. 6492324 - APJ ligand polypeptides (2002-12-10),

10. 6399316 - PACAP receptor protein, method for preparing said protein, and use thereof (2002-06-04),

11. 6228984 - Polypeptides their production and use (2001-05-08),

12. 5973117 - PACAP receptor protein, method for preparing said protein, and use (1999-10-26),

13. 5858787 - DNA encoding PACAP receptor protein and method for preparing said protein (1999-01-12),

Title: Innovator Spotlight: Yugo Habata

Introduction: Yugo Habata is a prominent inventor based in Tsukuba, Japan, who has made significant contributions to the fields of biochemistry and pharmaceutical sciences. With a total of 13 patents to his name, Habata's work focuses on innovations that hold potential for advancements in drug development and disease treatment.

Latest Patents: Among his latest patents, one noteworthy invention is the development of FPRL1 ligands and their applications. This patent describes a method that utilizes FPRL1 ligands, which have amino acid sequences closely related to SEQ ID NO: 1, SEQ ID NO: 17, or SEQ ID NO: 21. The invention allows for the efficient screening of FPRL1 agonists or antagonists, which can be pivotal in therapeutic settings. Another significant patent pertains to novel polypeptides that modulate various bodily functions, including central nervous system, circulatory, immune, gastrointestinal, metabolic, and reproductive functions. These polypeptides are proposed for use as drugs in preventing or treating diseases, such as HIV infection or AIDS.

Career Highlights: Yugo Habata has a robust background in pharmaceutical research, having worked with notable companies such as Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited. His innovative contributions to drug discovery and development have positioned him as a key figure in the industry.

Collaborations: Throughout his career, Habata has collaborated with esteemed colleagues, including Masaki Hosoya and Chieko Kitada. These partnerships have enriched his research endeavors and contributed to the successful development of his patented innovations.

Conclusion: Yugo Habata stands out as a leading inventor with a remarkable portfolio of patents that continue to influence the pharmaceutical landscape. His dedication to advancing medical science underscores the importance of innovation in the quest to tackle pressing health challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.